Results 51 to 60 of about 233,577 (305)

Nanotechnology advances for biomedical applications

open access: yesFrontiers in Nanotechnology
Nanotechnology has recently emerged as a revolutionary force in the field of biomedical science, offering innovative solutions to complex challenges in diagnostics, drug delivery, tissue engineering, and disease therapeutics.
Lekshmi Gangadhar, Saranyadevi Subburaj
doaj   +1 more source

Differential expression of cancer‐related genes supports prediction of poor response to first‐line treatments in T‐ALL pediatric patients with high minimal residual disease

open access: yesMolecular Oncology, EarlyView.
In the present work, we have identified a transcriptional signature based on the differential expression of six genes (BCL2&MAST4, HSH2D&LAT2, METRN&PITPNM2) that would facilitate the early detection of T‐cell acute lymphoblastic leukemia (T‐ALL) patients prone to a poor treatment response and could be implemented at diagnosis, along with other risk ...
Antonio Lahera   +11 more
wiley   +1 more source

Oral commercial Chinese polyherbal preparations combined with conventional biomedicine for pulmonary tuberculosis: network meta-analysis

open access: yesFrontiers in Pharmacology
BackgroundDespite therapeutic interventions, tuberculosis (TB) remains a persistent challenge. Combination therapy integrating Traditional Chinese Medicine (TCM) with conventional anti-TB medications demonstrates therapeutic benefits, necessitating a ...
Jiankang Jiang   +12 more
doaj   +1 more source

E2A selectively regulates TGF‐β–induced apoptosis in KRAS‐mutant non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
Ability to induce apoptosis by TGF‐β is frequently lost in advanced lung adenocarcinoma despite intact TGF‐β signaling. We identify E2A as a mutant KRAS–dependent mediator of resistance to TGF‐β–induced apoptosis. TGF‐β induces E2A via SMAD3 in mutant KRAS cells, and E2A silencing restores apoptosis and enhances radiation response in cell lines ...
Sergei Chuikov   +3 more
wiley   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

open access: yesMolecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau   +8 more
wiley   +1 more source

Informed consent to the receipt and use of human cellular material: juristic and ethical regulation

open access: yesРоссийский кардиологический журнал, 2018
Further progress in medicine is closely related to the clinical introduction of regenerative technologies, including cell therapy. Presented article covers the ethical and legal status of obtaining an informed consent from donors of cell material.
D. V. Stambolsky   +7 more
doaj   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

open access: yesMolecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan   +16 more
wiley   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

open access: yesMolecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain   +10 more
wiley   +1 more source

Longitudinal circulating tumor DNA profiling in patients with advanced endometrial cancer using an off‐the‐shelf targeted NGS panel

open access: yesMolecular Oncology, EarlyView.
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena   +15 more
wiley   +1 more source

Monoclonal Antibodies to Migraine: Witnesses to modern biomedicine, an A-Z

open access: yes, 2014
The History of Modern Biomedicine Research Group hosted its first Witness Seminar, on monoclonal antibodies, in 1993. Since then more than sixty such meetings have been held, the most recent on migraine in 2013.
Tansey, EM
core  

Home - About - Disclaimer - Privacy